Publication:
Current and emerging therapies in peripheral T-cell lymphoma: Focus on pralatrexate

Simple item page
dc.contributor.authorThanyanan Reungwetwattanaen_US
dc.contributor.authorSylvia Jaramilloen_US
dc.contributor.authorJulian R. Molinaen_US
dc.contributor.otherMayo Medical Schoolen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-05-03T08:43:09Z
dc.date.available2018-05-03T08:43:09Z
dc.date.issued2011-01-01en_US
dc.description.abstractPeripheral T-cell lymphomas (PTCL) represent about 12%-15% of non-Hodgkin lymphomas and are characterized for being a molecularly heterogenous group of diseases. The optimal treatment for PTCLs remains to be defined as they are usually refractory to existing therapies and carry a poor prognosis. Pralatrexate (PDX), a rationally designed antifolate drug, was granted FDA approval as a single agent for the treatment of relapsed/refractory PTCL in 2009. Because of its favorable toxicity profile and activity, Pralatrexate has become a major compound for patients with refractory PTCL. © the author(s), publisher and licensee Libertas Academica Ltd.en_US
dc.identifier.citationClinical Medicine Insights: Therapeutics. Vol.3, (2011), 125-135en_US
dc.identifier.doi10.4137/CMT.S3778en_US
dc.identifier.issn1179559Xen_US
dc.identifier.issn1179559Xen_US
dc.identifier.other2-s2.0-79957788903en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/12830
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79957788903&origin=inwarden_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleCurrent and emerging therapies in peripheral T-cell lymphoma: Focus on pralatrexateen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79957788903&origin=inwarden_US

Files

Collections

Scopus 2011-2015